Leap Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Leap Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Leap Therapeutics Inc Strategy Report
- Understand Leap Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Leap Therapeutics Inc (Leap Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with different types of cancer. The company’s pipeline products include DKN-01. DKN-1 is a monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, prostate cancer and gynecologic cancer. FL-301, a monoclonal antibody that targets Claudin18.2, is being tested in patients with gastric and pancreatic cancer. The company has an agreement with BeiGene Ltd for development rights and commercialization of DKN-01 in Australia, Asia (excluding Japan) and New Zealand. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
47 Thorndike St Ste B1-1, Cambridge, Massachusetts, 02141-1799
Website
www.leaptx.com
Telephone
1 617 2524343
No of Employees
54
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LPTX (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-49.1%
(2022 vs 2021)
Market Cap*
$113.3M
Net Profit Margin (2020)
XYZ
-47.5%
(2022 vs 2021)
* As of and is in US$
Leap Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| DKN-01 - Gastroesophageal Cancer/ Prostate Cancer / Gynecologic Cancer |
| FL-301 (NBL-105) - Gastric/ Pancreatic |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, the company entered into an agreement with BeiGene for trial, a randomized controlled trial of DKN-01 in combination with BeiGene's anti-PD-1 antibody, tislelizumab, and chemotherapy in first-line gastric cancer patients, as a clinical collaboration with BeiGene supplying tislelizumab. |
| 2023 | Contracts/Agreements | In January, the company entered into an agreement to acquire Flame Biosciences, Inc. |
| 2022 | Contracts/Agreements | In January, the company entered into an agreement with Leica Biosystems to develop companion diagnostic tests to detect Dickkopf-related protein 1 (DKK1) for cancer therapy. |
Competitor Comparison
| Key Parameters | Leap Therapeutics Inc | Merck & Co Inc | Pfizer Inc | Bristol-Myers Squibb Co | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Cambridge | Kenilworth | New York | Princeton | Thousand Oaks |
| State/Province | Massachusetts | New Jersey | New York | New Jersey | California |
| No. of Employees | 54 | 72,000 | 88,000 | 34,100 | 26,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christopher K. Mirabelli, Ph.D. | Chairman | Executive Board | 2016 | 68 |
| Douglas E. Onsi | Director; Chief Executive Officer; President | Executive Board | 2020 | 54 |
| Augustine Lawlor | Chief Operating Officer | Senior Management | 2016 | 66 |
| Cyndi Sirard, M.D. | Chief Medical Officer | Senior Management | 2020 | 53 |
| Jason Baum, Ph.D. | Chief Scientific Officer | Senior Management | 2023 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward